The backtest results for ADXN show a 50% win rate across 3, 10, and 30 days following earnings beats, with returns improving over time from -0.39% at 3 days to 6.41% at 30 days. The maximum return reached 16.44% by day 14, indicating a delayed but significant positive price reaction. This suggests that while immediate gains are uncertain, holding ADXN for up to a month post-earnings beat can yield meaningful returns. Investors might consider a medium-term holding strategy to capitalize on the gradual price appreciation after positive earnings surprises.

backtest_data

The backtest results show that ADXN experienced a 66.67% win rate over 3, 10, and 30 days following earnings misses, with a notable 7.98% average return in the first 3 days. However, returns diminished over longer periods, dropping to 0.68% by 30 days. This suggests a strong short-term rebound despite the earnings miss, but limited sustained gains thereafter.

The pattern indicates that ADXN's stock price tends to recover quickly but does not maintain momentum long term after disappointing earnings.

Investors might consider short-term trading strategies to capitalize on the initial rebound post-earnings miss in ADXN.

The backtest results show that when the Pharmaceuticals Industry beats earnings expectations, the average impact on the industry is slightly negative, with a maximum return of -0.41% occurring one day after the event. This suggests that despite positive earnings surprises, the sector does not experience immediate positive price reactions. The analysis indicates that other factors may be influencing the sector's performance post-earnings beat, possibly dampening investor enthusiasm.

Investors should be cautious about expecting gains solely based on earnings beats in this industry and consider broader market or sector conditions before making investment decisions.

The backtest results show that the Pharmaceuticals Industry experiences a slight negative impact following earnings misses, with a maximum return decline of 0.15% occurring around day 8. This indicates a consistent but modest adverse market reaction to earnings underperformance within this sector over the tested period.

The analysis suggests that while the negative effect is present, its magnitude is limited, implying that the industry is somewhat resilient to earnings misses. Investors should be cautious but not overly reactive to such events in this sector.

Investment strategies might focus on monitoring earnings quality but avoid drastic position changes solely based on earnings misses in Pharmaceuticals.

Backtest ADXN Earning Beats Expectations

Find all upcoming company earnings reports scheduled for mar 09 2026. Get details on which companies are reporting and their expected results.

Calendar